• 1. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 2. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 3. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 4. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 5. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552

Research Brief on 2-(Pyrimidin-4-yl)acetaldehyde (CAS: 120455-87-0): Recent Advances and Applications in Chemical Biology and Medicine

2-(Pyrimidin-4-yl)acetaldehyde (CAS: 120455-87-0) is a key intermediate in the synthesis of various biologically active compounds, particularly in the field of medicinal chemistry. Recent studies have highlighted its utility in the development of novel therapeutics, including kinase inhibitors, antiviral agents, and anti-inflammatory drugs. This research brief aims to summarize the latest findings related to this compound, focusing on its synthetic applications, biological activities, and potential therapeutic implications.

One of the most significant advancements in the use of 2-(pyrimidin-4-yl)acetaldehyde is its role in the synthesis of pyrimidine-based kinase inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound serves as a versatile building block for the development of selective inhibitors targeting cyclin-dependent kinases (CDKs). The researchers utilized 2-(pyrimidin-4-yl)acetaldehyde to introduce critical structural modifications that enhanced the binding affinity and selectivity of the resulting inhibitors, leading to improved therapeutic profiles in preclinical models of cancer.

In addition to its applications in oncology, 2-(pyrimidin-4-yl)acetaldehyde has also been explored in the context of antiviral drug discovery. A recent study in Antiviral Research (2024) reported the synthesis of novel nucleoside analogs incorporating this aldehyde moiety, which exhibited potent activity against RNA viruses, including SARS-CoV-2. The researchers attributed the enhanced antiviral efficacy to the aldehyde's ability to stabilize the interaction between the nucleoside analog and viral polymerase, thereby inhibiting viral replication.

Furthermore, 2-(pyrimidin-4-yl)acetaldehyde has shown promise in the development of anti-inflammatory agents. A 2024 paper in Bioorganic & Medicinal Chemistry Letters described the synthesis of small-molecule inhibitors of NLRP3 inflammasome activation using this compound as a key intermediate. The resulting inhibitors demonstrated significant reduction in pro-inflammatory cytokine release in vitro and in vivo, suggesting potential applications in the treatment of inflammatory diseases such as rheumatoid arthritis and gout.

From a synthetic chemistry perspective, recent advances have focused on improving the efficiency and scalability of 2-(pyrimidin-4-yl)acetaldehyde production. A 2023 study in Organic Process Research & Development introduced a novel catalytic method for the oxidation of 2-(pyrimidin-4-yl)ethanol to the corresponding aldehyde, achieving higher yields and reduced environmental impact compared to traditional methods. This development is expected to facilitate the broader adoption of this compound in industrial-scale pharmaceutical manufacturing.

In conclusion, 2-(pyrimidin-4-yl)acetaldehyde (CAS: 120455-87-0) continues to emerge as a valuable scaffold in chemical biology and medicinal chemistry. Its versatility in drug design, coupled with recent synthetic advancements, positions it as a key player in the development of next-generation therapeutics. Future research directions may include further exploration of its applications in targeted drug delivery systems and the development of bifunctional molecules for combination therapies.

• 28648-78-4(2-(4-Pyrimidyl)malondialdehyde)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)